



Certificate of Mailing (37 C.F.R. §1.8):

I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail in an envelope addressed to:  
Mail Stop: DD, Commissioner for Patents,  
PO Box 1450, Alexandria, VA 22313-1450  
on this 29th day of May 2003.

s/ Danielle Dixon  
Danielle Dixon

RECEIVED  
JUN 04 2003  
TECH CENTER 1600/2900

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the Application of:  
Michele A. McTigue et al.

Group Art Unit: 1637

Serial No.: 09/939,754

Examiner: To Be Assigned

Filed: August 28, 2001

For: MODIFICATIONS OF THE VEGF  
RECEPTOR-2 PROTEIN AND METHODS OF  
USE

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT  
UNDER 37 CFR 1.97(c)

Mail Stop: DD  
Commissioner For Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

Pursuant to the duty of disclosure under 37 CFR 1.56, Applicant brings the art documents listed on the attached Form PTO-SB/08A to the attention of the Examiner for consideration in connection with the examination of the above-identified application.

This Information Disclosure Statement is being filed within the period specified at 37 CFR 1.97(c)-i.e., (1) the Information Disclosure Statement is filed before the mailing date of any of a final action under 1.113, a notice of allowance under 1.311, or an action that otherwise closes prosecution in the application, and it is accompanied by a statement which specifies that each item of the information contained in the information disclosure statements was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three month prior to the filing of the information disclosure statement.

The prior art disclosed in this Supplemental Information Disclosure Statement was cited in a related foreign application search report, which is enclosed for your convenience.

The following documents cited in the European Search Report were previously cited in the Information Disclosure Statement filed with the USPTO on September 28, 2001:

- Heidaran et al., "Deletion or Substitution within the  $\alpha$  Platelet-Derived Growth Factor Receptor Kinase Insert Domain: Effects On Functional Coupling with Intracellular Signaling Pathways," *Molecular and Cellular Biology* (Jan. 1991) pages 134-142;


- Severinsson, et al., "Deletion Of The Kinase Insert Sequence Of The Platelet-Derived Growth Factor  $\beta$ -Receptor Affects Receptor Kinase Activity And Signal Transduction" *Molecular and Cellular Biology* (Feb. 1990) pages 801-809;
- Mahammadi, et al., "Structure of the FGF Receptor Tyrosine Kinase Domain Reveals a Novel Autoinhibitory Mechanism" *Cell* (August 23, 1996) Vol. 86, pages 577-587; and
- Taylor et al., "The Unique Insert Of Cellular And Viral *fms* Protein Tyrosine Kinase Domains Is Dispensable For Enzymatic And Transforming Activities," *The EMBO Journal* (1989) Vol. 8 No. 7, pages 2029-2037.

A copy of the cited document disclosed in the Form PTO.SB/08A is enclosed. The cited art document is in the English language.

It is respectfully requested that the Examiner confirm consideration of the cited document by initialing the attached Form PTO.SB/08A and returning a copy of the initialed form to Applicant.

No fee is believed to be due at this time. However, if the applicant is incorrect, please charge all required fees to Deposit Account No. 500329.

Respectfully submitted,

  
Joseph F. Reidy  
Registration No. 39,340

Date: May 29, 2003

Agouron Pharmaceuticals, Inc./A Pfizer Company  
10777 Science Center Drive  
San Diego, CA 92121  
Fax: 858-678-8233  
Phone: 858-622-7320

U.S. Patent and Trademark Office; U.S. Department of Commerce

**Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control Number.**


**Substitute for form 1449/PTO**



**INFORMATION DISCLOSURE  
STATEMENT BY APPLICATION**

<b>Complete if Known</b>	
Application Number	09/939,754
Filing Date	August 28, 2001
First Named Inventor	Michele McTigue
Art Unit	1637
Examiner Name	To be assigned
Attorney Docket Number	0069-04-US

## **U.S. PATENT DOCUMENTS**



## **FOREIGN PATENT DOCUMENTS**

EXAMINER INITIAL	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>8</sup>
		Country Code3 Number4 Kind Code5 (if known)				

EXAMINER:	DATE CONSIDERED:
-----------	------------------

**EXAMINER:** Initial if reference considered, whether or not a citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1Applicant's unique citation designation number (optional). 2See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901-04. 3Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5Kindof document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public, which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. Send to: Mail Stop: DD, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICATION**  
 (Use as many sheets as necessary)
**Complete if Known**

Application Number	09/939,754
Filing Date	August 28, 2001
First Named Inventor	Michele McTigue
Art Unit	1637
Examiner Name	To be assigned
Attorney Docket Number	0069-04-US

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	A	MCTIGUE, et al., "Crystal Structure Of The Kinase Domain Of Human Vascular Endothelial Growth Factor Receptor 2: A Key Enzyme In Angiogenesis," <i>Structure</i> (1999) Vol. 7, No. 3, pages 319-330.	

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if reference considered, whether or no citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application. <sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901-04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the parent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public, which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. Send to: Mail Stop: DD, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.